Beyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction
US Cardiology Review · 05.08.2026
DOI: 10.15420/usc.2025.20 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift US Cardiology Review, online erschienen am 05.08.2026. Verfasst von Rebecca S Steinberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiovascular Disease, Duke University School of Medicine Durham, NC. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Recent data suggest that sodium–glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium–glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Cardiovascular Disease, Duke University School of Medicine Durham, NC.
- CardioNerds Academy, CardioNerds Baltimore, MD.
- Department of Medicine, Division of Cardiovascular Disease, Allegheny General Hospital Pittsburgh, PA.
- Department of Internal Medicine, Baylor University Medical Center Dallas, TX.
- Department of Medicine, Rutgers New Jersey Medical School Newark, NJ.
- Department of Medicine, University of Miami/Jackson Memorial Hospital Miami, FL.
ORCID-Profile: Rebecca S Steinberg, Ritika Tuli, Shivani Reddy, Rafael Toro-Manotas, Natalie Marrero
Zitieren
APA
Steinberg, R. S., Tuli, R., Reddy, S., Toro-Manotas, R., Marrero, N., Balanescu, D. V., & Mysore, M. M. (2026). Beyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction. US Cardiology Review. https://doi.org/10.15420/usc.2025.20
Vancouver
Steinberg RS, Tuli R, Reddy S, Toro-Manotas R, Marrero N, Balanescu DV, et al. Beyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction. US Cardiology Review. 2026. doi:10.15420/usc.2025.20
BibTeX
@article{Steinberg2026,
author = {Steinberg, Rebecca S and Tuli, Ritika and Reddy, Shivani and Toro-Manotas, Rafael and Marrero, Natalie and Balanescu, Dinu V and Mysore, Manu Murali},
title = {Beyond Hyperglycemia: The Role of Sodium–Glucose Cotransporter 2 Inhibitors in Cancer Treatment-related Cardiac Dysfunction},
journal = {US Cardiology Review},
year = {2026},
doi = {10.15420/usc.2025.20}
}
EUVIMED